Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17684177 | 0.94 | SLC6A9 (0.34) | SLC6A9PDE2AMAPK1P2RX7 | |
| SCHEMBL17684738 | 0.91 | SLC6A9 (0.39) | SLC6A9 | |
| SCHEMBL17683902 | 0.91 | SLC6A9 (0.38) | SLC6A9PDE2A | |
| SCHEMBL17684362 | 0.90 | SLC6A9 (0.39) | SLC6A9 | |
| SCHEMBL17683975 | 0.89 | SLC6A9 (0.44) | SLC6A9MAPK1 | |
| SCHEMBL17684124 | 0.88 | PDE2A (0.37) | SLC6A9PDE2AMAPK1 | |
| SCHEMBL17683974 | 0.88 | SLC6A9 (0.38) | SLC6A9PDE2AMAPK1P2RX7 | |
| SCHEMBL17684178 | 0.87 | SLC6A9 (0.45) | SLC6A9PDE2AMAPK1 | |
| SCHEMBL17684025 | 0.86 | SLC6A9 (0.39) | SLC6A9PDE2AMAPK1P2RX7 | |
| SCHEMBL17684609 | 0.86 | SLC6A2 (0.41) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | claimed |
| EP-3009421-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | claimed |
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3009421-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009421-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | SLC1A2, SLC6A5, SLC18A2 | SLC6A9 13/4885PDE2A 2475/4885MAPK1 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.